Sun Pharma partner Philogen resubmits Nidlegy MAA to EMA

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹1973.00

prior close

₹1978.80

announcement price

After-mkt

timing

Nifty 100market-0.2%+0.4% vs market

Pharmaceuticals peers, median of 165sector-0.8%+1.1% vs sector

On the reaction day the stock moved 0.4 pts more than Nifty 100 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

+0.1

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3-0.2+0.4-0.8+1.1

Next day

+0.9+0.9+0.1+0.2+0.7

+1.6+1.1+0.5-0.7+2.4

+0.6+1.6-1.0-0.3+0.9

-1.4+3.2-4.6+0.3-1.7

-0.5+2.5-3.0+0.7-1.2

-1.1+2.7-3.8+0.3-1.4

15d

-5.0+1.0-5.9+1.1-6.1

-2.7+1.0-3.7+1.6-4.2

-6.8-4.7-2.1+2.4-9.2

-10.9-5.8-5.2-2.0-8.9

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sun Pharma's partner Philogen resubmitted the Marketing Authorization Application for Nidlegy to the European Medicines Agency for neoadjuvant treatment of locally advanced, fully resectable melanoma. The updated application is based on Phase III PIVOTAL study data with 33 months median follow-up, up from 21 months, and includes additional event-free survival analyses and manufacturing information. Nidlegy is partnered with Sun Pharma for skin cancers in Europe, New Zealand and Australia.

Likely market impact

Positive step for Sun Pharma's dermatology pipeline. No immediate revenue impact since approval is still pending review by the European Medicines Agency.